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A 17-year-old high school student who has never been pregnant presents for advice 
regarding contraception. She has an unremarkable medical history and is planning 
to become sexually active with her boyfriend in the near future. Her primary concern 
is an unintended pregnancy, and she inquires about methods of contraception that 
are highly effective. How would you counsel her about options for contraception?
The Clinic a l Problem
Unintended pregnancies are a difficult public health problem for clinicians and policy makers. After three decades of minimal change in the rate of unintended pregnancy in the United States among adolescents 
and women, the rate has decreased in recent years — from 54 unintended preg-
nancies per 1000 adolescents and women 15 to 44 years of age in 2008 to 45 
cases per 1000 adolescents and women in 2011.1 However, the most recent U.S. 
data still indicate that 45% of all pregnancies in the United States are unintended, 
as compared with 34% in Western Europe.1,2 Unintended pregnancies are associated 
with an increased risk of adverse reproductive outcomes and sociodemographic 
challenges; contraception is a primary means of prevention. Overall, between 2011 
and 2013, a total of 62% of all women 15 to 44 years of age reported current use 
of contraception.3,4 However, the most highly effective, reversible methods — intra-
uterine devices (IUDs) and hormonal implants — were being used by only a small 
proportion of the women who reported using contraceptives between 2011 and 
2013. A comparison of the use of IUDs and hormonal implants between 2002 and 
2011–2013 showed that the use of IUDs increased from 2% to 10% and the use of 
implants increased from 0.4% to 1% (Fig. S1 in the Supplementary Appendix, 
available with the full text of this article at NEJM.org).3,4 Increasing access to these 
most effective, reversible methods of contraception is a key strategy to further 
decrease the rate of unintended pregnancy in the United States.
S tr ategies a nd E v idence
Long-acting reversible contraception, or LARC, methods provide reliable, long-term, 
highly effective prevention of pregnancy after one-time placement of a device. 
LARC methods include IUDs (hormonal IUDs and nonhormonal copper-containing 
IUDs) and the subdermal hormonal implant (Fig. 1). These methods are sometimes 
termed “forgettable”5; they do not depend on user adherence such as taking a pill 
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daily, receiving an injection every 3 months, or 
placing a ring or patch. Consequently, LARC 
methods are highly effective — approximately 
20 times as effective as pills, patches, or rings.6 
Among teenage girls and women enrolled in the 
Contraceptive CHOICE Project, a prospective 
cohort study involving almost 10,000 women in 
the St. Louis area who received tiered, compre-
hensive contraceptive counseling (in order of 
effectiveness, from LARC methods to barrier 
methods) and were provided contraception at no 
cost, pregnancy rates were 5 pregnancies per 
100 participant-years among pill, patch, and ring 
users as compared with 0.3 pregnancies per 100 
participant-years among LARC users.6 Young age 
(<21 years) doubled the failure rates among pill, 
patch, and ring users but had no effect on failure 
rates among LARC users.6
IUDs
As of November 2016, five IUDs were approved 
by the Food and Drug Administration (FDA) and 
were available in the United States. The copper-
containing IUD, ParaGard, is a nonhormonal de-
vice and contains 380 mm2 of copper around the 
arms and stem. The four levonorgestrel-releasing 
IUDs (LNG-IUDs) include two devices that con-
tain 52 mg of levonorgestrel (Mirena and Liletta), 
a device that contains 19.5 mg (Kyleena), and a 
slightly smaller device that contains 13.5 mg 
(Skyla). Liletta is marketed as a lower-cost alter-
native for clinics eligible for 340B pricing through 
the Department of Health and Human Services.7 
There has been widespread confusion regarding 
the mechanism of action of the IUD. IUDs do 
not cause the destruction of an implanted em-
bryo but rather work primarily by preventing 
fertilization.8 The copper-containing IUD re-
leases copper ions that are toxic to sperm.8 The 
LNG-IUD inhibits ovulation and thickens cervi-
cal mucus, which obstructs the penetration of 
sperm.9 Less than 1% of women become pregnant 
during the first year of IUD use, with pregnancy 
rates with the LNG-IUD (0.1 to 0.2%) generally 
reported as lower than the rates with the copper-
containing IUD (0.5 to 0.8%).10-12 ParaGard is 
approved by the FDA for 10 years of use, Mirena 
and Kyleena for 5 years, and Skyla for 3 years. As 
of November 2016, Liletta is approved for 3 years 
of use, but data are being collected to assess 
5-year use. In the Contraceptive CHOICE Project, 
continuation rates with the LNG-IUD and the 
copper-containing IUD were 88% and 85%, re-
spectively, at 1 year, 79% and 77% at 2 years, and 
52% and 56% at 5 years.13,14 In other studies in-
volving various populations in the United States, 
12-month IUD continuation rates of 87 to 89% 
have been reported.15,16
Almost all women can safely use IUDs. Excep-
tions include women who have hypersensitivity 
to copper, which would preclude the use of the 
copper-containing IUD, or hypersensitivity to 
other components of either type of IUD; women 
with a current pelvic infection or a sexually 
transmitted disease (STD); women with gyneco-
logic cancers; and women with certain other 
serious medical conditions (Table 1).17 Women 
who have current purulent cervicitis or known 
chlamydial infection or gonococcal infection 
should not undergo insertion of an IUD. Women 
generally do not require screening for STDs at 
the time of IUD insertion if they have already 
Key Clinical Points
Long-Acting Reversible Contraception
• Intrauterine	devices	(IUDs)	and	hormonal	implants	are	the	most	effective	reversible	methods	of
contraception — approximately 20 times as effective as pills, patches, and rings; couples should be 
counseled and informed about the superior effectiveness of long-acting reversible contraception 
(LARC) methods.
• IUDs	and	hormonal	implants	are	safe	for	almost	all	women,	including	adolescents,	as	well	as	women	in
the postpartum or postabortion period.
• The	main	side	effect	of	IUDs	and	hormonal	implants	is	a	change	in	bleeding	patterns;	anticipatory
counseling about expected changes in bleeding may increase rates of continuation.
• Barriers	to	access	to	IUDs	and	hormonal	implants	remain,	including	those	related	to	education,
provider training, cost, and logistics; successful interventions have been shown to minimize these 
barriers.
• Adolescents	and	adult	women	should	be	counseled	about	contraception	and	should	have	access	to	the
full range of contraceptive methods, including LARC methods.
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been screened according to the STD Treatment 
Guidelines of the Centers for Disease Control 
and Prevention (CDC) (e.g., annual screening for 
chlamydial infection for women younger than 
25 years of age or for older women at increased 
risk for STDs).18 If a woman with risk factors for 
STDs has not been screened according to the 
guidelines, screening can be performed at the 
time of insertion of the IUD, and insertion 
should not be delayed (Table 2).19 Women who 
have cervical or endometrial cancers should not 
undergo IUD insertion but may continue to use 
an IUD while awaiting cancer treatment.17 Given 
theoretical concerns about the adverse effects 
of progestin on breast cancer, the use of the 
LNG-IUD is considered to be contraindicated in 
women with current breast cancer and is gener-
ally not recommended in women who had recent 
breast cancer; however, evidence to assess this 
concern is limited.17
A common side effect of using a copper-
containing IUD is increased menstrual bleed-
ing; in contrast, the LNG-IUD generally reduces 
heavy menstrual bleeding.19 Anticipatory coun-
seling regarding expected changes in bleeding 
may increase rates of IUD continuation. For 
women with copper-containing IUDs who re-
quest treatment for their heavy bleeding, a short 
course (5 to 7 days) of a nonsteroidal antiin-
flammatory drug may decrease bleeding.19
The copper-containing IUD can also be used 
as emergency contraception (inserted after sexu-
al intercourse to prevent pregnancy). For women 
who meet eligibility requirements for IUD inser-
tion and who have had unprotected sex within 
the previous 5 days, the copper-containing IUD 
is the most effective form of emergency contra-
ception and has the benefit of becoming a long-
term contraceptive method.19,20
 Subdermal Hormonal Implant
Currently, Nexplanon is the only hormonal im-
plant available in the United States. Nexplanon, 
which slowly releases the progestin etonoges-
trel, differs from a similar previous implant, 
Implanon, in that it has an improved inserter 
and contains barium to facilitate the radiologic 
detection of implants that cannot be palpated. 
The contraceptive mechanism of action of the 
hormonal implant is twofold: inhibition of ovu-
lation and thickening of the cervical mucus. The 
contraceptive effectiveness of the implant is 
high, with an estimated 0.1% of users becoming 
pregnant in the first year of use,10,21 and does 
not seem to vary with body-mass index.21,22 The 
etonogestrel-releasing implant is approved by 
the FDA for 3 years of use. Data from the Con-
traceptive CHOICE Project showed that young 
women 14 to 19 years of age reported high con-
tinuation rates (82% at 12 months).23 In other 
studies involving various populations in the 
United States, implant continuation rates of 75 
to 83% at 12 months have been reported,15,24 and 
a large, multicountry study showed continuation 
rates of 88% at 1 year and 70% at 2.5 years.21
Almost all women can safely use implants; 
exceptions are women who have hypersensitiv-
ity to barium or to the components of the im-
plant. Given theoretical concerns about the 
adverse effects of progestin on breast cancer, 
the use of the hormonal implant is considered to 
be contraindicated in women with current breast 
Figure 1. Long-acting Reversible Contraceptive Methods.
Shown are examples of a hormonal intrauterine device 
(IUD) (Panel A), a nonhormonal, copper-containing IUD 
(Panel B), and a subdermal hormonal implant (Panel C).
Hormonal implant
placed subdermally
Actual size (40 mm by 2 mm)
A B
C
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cancer and is generally not recommended in 
women who have had recent breast cancer.17 The 
most common side effect of implants is unpre-
dictable bleeding, and women should be coun-
seled about this risk before implant place-
ment.19,25 Although amenorrhea may occur in 
approximately 20% of women, irregular uterine 
bleeding, unpredictable uterine bleeding and 
spotting, or both are common and may persist 
over time.25
Condition Category of Medical Eligibility Criteria Comments
Copper-
Containing 
IUD LNG-IUD Implant
Pregnancy 4 4 NA The	use	of	an	implant	is	not	needed;	no	known	harm	
to the woman, to the course of her pregnancy, or to 
the fetus occurs if an implant is inadvertently used 
during pregnancy.
Distorted uterine cavity incompatible with 
IUD placement
4 4 NA An anatomical abnormality that distorts the uterine 
cavity might preclude proper IUD placement.
Current pelvic inflammatory disease, gono-
coccal or chlamydial infection, or puru-
lent cervicitis
4 4 1 Insertion of an IUD might worsen the condition.
Postpartum or postabortion sepsis 4 4 NA Insertion of an IUD might worsen the condition.
Persistent intrauterine gestational tropho-
blastic disease
4 4 1 An IUD should not be inserted because of the theoreti-
cal risk of perforation, infection, and hemorrhage.
Cervical cancer 4 4 2 Concern exists about the increased risk of infection 
and	bleeding	at	insertion.	The	IUD	will	probably	
need to be removed at the time of cancer treatment.
Endometrial cancer 4 4 1 Concern exists about the increased risk of infection, 
perforation,	and	bleeding	at	insertion.	The	IUD	will	
probably need to be removed at the time of cancer 
treatment.
Unexplained vaginal bleeding (raising sus-
picion of serious condition)
4 4 3 If pregnancy or an underlying pathologic condition 
(e.g., pelvic cancer) is suspected, it must be eval-
uated and the category adjusted after evaluation. 
Irregular bleeding patterns associated with the 
method used might mask symptoms of underlying 
pathologic conditions.
Current breast cancer 1 4 4 Hormonal stimulation may worsen the condition.
History of breast cancer with no evidence  
of disease for 5 years
1 3 3 —
Complicated solid-organ transplantation 3 3 2 Data on risks and benefits are limited in this population.
Systemic lupus erythematosus (with severe 
thrombocytopenia)
3 2 2 Concern exists about an increased risk of bleeding.
Systemic lupus erythematosus (with positive 
or unknown antiphospholipid antibodies)
1 3 3 Concern exists about an increased risk of both arterial 
and venous thrombosis.
Severe, decompensated cirrhosis 1 3 3 Hormonal exposure may worsen the condition.
Hepatocellular adenoma or hepatic malignancy 1 3 3 Hormonal exposure may worsen the condition.
*		This	table	is	adapted	from	Curtis	et	al.17 and includes only the subset of conditions for which at least one of the three long-acting reversible
contraception (LARC) methods was categorized as either MEC 3 or MEC 4; all other conditions, which were categorized as either MEC 1 or
MEC 2 for all three LARC methods, are included in the complete MEC guidance document (Curtis et al.17). Categories of MEC for the use of
LARC methods are defined as follows: MEC 4, unacceptable health risk, indicating that the LARC method should not be used; MEC 3, theo-
retical or proven risks usually outweigh the advantages, indicating that the LARC method should not generally be used; MEC 2, advantages
outweigh theoretical or proven risks; and MEC 1, no restriction. IUD denotes intrauterine device, LNG-IUD levonorgestrel-releasing IUD,
and NA not applicable.
Table 1. Medical Eligibility Criteria (MEC) for Initiation of LARC Methods — Conditions for which at Least One LARC Method Should Not Be 
Used (MEC 4) or Should Not Generally Be Used (MEC 3).*
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Use of LARC Methods in Specific Populations
LARC methods are safe for use in almost all 
women, including young and nulliparous wom-
en.17,26 Providers may be concerned about the 
risks of pelvic inflammatory disease (PID) and 
infertility associated with the use of IUDs, par-
ticularly in young or nulliparous women.27 How-
ever, evidence has shown that the risk of PID 
associated with the insertion and use of IUDs is 
minimal. Data from more than 50,000 woman-
years of IUD use indicated a rate of 9.7 cases of 
PID per 1000 woman-years in the first 20 days 
after IUD insertion, which then dropped to 1.4 
cases of PID per 1000 woman-years over the 
course of 8 years of follow-up.28 More recent 
studies conducted in the United States have also 
shown low rates of PID after IUD insertion: less 
than 1% among 57,728 women within 90 days 
after IUD insertion, even in the absence of STD 
screening,29 and 1% or less among participants 
in the Contraceptive CHOICE Project.30 The 
LNG-IUD may, in fact, protect against PID; a 
randomized, controlled trial involving 2758 wom-
en showed that the risk of PID was lower among 
LNG-IUD users than among users of a copper-
containing IUD (Nova-T) after 36 months of use.31 
Observational studies have also shown that in-
fertility was associated with a history of STDs 
and not a history of IUD use.32,33
Both IUDs and implants are safe for use in the 
postpartum and postabortion periods, including 
immediately post partum and post abortion17,26; 
immediate placement has been associated with 
lower rates of rapid repeat pregnancy and repeat 
abortions than the rates with other contracep-
tives.26,34 Insertion of an IUD immediately post 
partum is associated with low rates of adverse 
events such as perforation (0 in three studies of 
over 3000 women in total), infection (1% in one 
study of 554 women), and the need for removal 
of the IUD as a result of bleeding and pain (5 to 
11% over 12 months in three studies of approxi-
mately 7500 women in total); these rates gener-
ally did not differ from those observed with IUD 
insertion at times other than the postpartum 
period.35 Uterine perforation, although rare, may 
be more prevalent among women who are breast-
feeding (5.6 cases per 1000 IUD insertions 
through 36 weeks post partum in one study) 
than among women who are not breast-feeding, 
although this finding is not consistent across 
studies.36 Among women who are breast-feeding, 
the use of an IUD or implant is not associated 
with differences in the proportions of women 
who initiate breast-feeding or in the duration of 
exclusive or partial breast-feeding, or with adverse 
health outcomes in the infant.36,37 Although the 
risk of thromboembolism associated with LARC 
use has not been well studied, these methods 
of contraception do not contain estrogen and 
therefore are not associated with the same po-
tential for thromboembolism in the postpartum 
Contraceptive Method
Timing 
of Initiation†
Additional Contraception Needed 
as Back-up‡
Examinations or Tests 
Needed before Initiation
Copper-containing 
IUD
Any time Not needed Bimanual examination and 
cervical inspection§
Levonorgestrel-
releasing IUD
Any time If more than 7 days after menses start-
ed, use back-up method or abstain 
from sexual intercourse for 7 days.
Bimanual examination and 
cervical inspection§
Hormonal implant Any time If more than 5 days after menses start-
ed, use back-up method or abstain 
from sexual intercourse for 7 days.
None
*		This	table	is	adapted	from	Curtis	et	al.19
†  LARC methods can be initiated if the provider is reasonably certain that the woman is not pregnant.
‡		The	recommendations	for	the	use	and	duration	of	a	back-up	method	were	determined	on	the	basis	of	the	mechanism	
of action of the contraceptive method and on the basis of data on the minimum duration of use necessary for contra-
ceptive effectiveness.
§	 	Most	women	do	not	require	additional	screening	for	sexually	transmitted	diseases	(STDs)	at	the	time	of	insertion	of	an
IUD.	If	a	woman	with	risk	factors	for	STDs	has	not	been	screened	for	gonococcal	infection	and	chlamydial	infection	ac-
cording	to	the	STD	Treatment	Guidelines	of	the	Centers	for	Disease	Control	and	Prevention	(CDC)	(www	.	cdc	.	gov/	std/	
 treatment), screening can be performed at the time of IUD insertion, and insertion should not be delayed. Women with 
current purulent cervicitis or chlamydial infection or gonococcal infection should not undergo IUD insertion.
Table 2. Selected Practice Recommendations for the Initiation of LARC Methods.*
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period as are estrogen-containing contracep-
tives.38
Although IUDs are generally safe for use in 
the postpartum period, the relative risk of expul-
sion of IUDs that are placed immediately post 
partum is higher than the risk with IUDs placed 
at 6 weeks post partum or later.39 Expulsion rates 
vary widely by study population but are gener-
ally lower when the IUD is inserted immediately 
after delivery of the placenta (3 to 27%) than 
when it is inserted 10 minutes to 48 hours after 
delivery of the placenta (11 to 27%); both rates 
are higher than those with standard insertion 
at 4 to 8 weeks post partum (0 to 6%).39 Trials 
that compared immediate versus delayed IUD 
insertion during either the postpartum or post-
abortion period showed that even with higher 
expulsion rates after immediate insertion, IUD 
continuation rates at 6 to 12 months were gener-
ally higher among the women whose IUDs were 
placed immediately post partum or post abor-
tion.39,40
A r e a s of Uncerta in t y
Although the use of IUDs and hormonal im-
plants in the United States has been increasing, 
several barriers continue to limit access to these 
methods. The Contraceptive CHOICE Project 
showed that when women were counseled about 
all contraceptive methods in order of effective-
ness and contraception was provided at no cost, 
high percentages of women, including teenage 
girls, chose LARC methods (any LARC method, 
75%; IUD, 58%; and implant, 17%).41,42 Other 
barriers to accessing LARC include a lack of 
trained providers,27,43 low reimbursement for LARC 
supplies and services,44 a lack of immediate 
LARC access at the clinical site where the method 
is requested,43 and extra steps and visits, such as 
unnecessary screening tests before the initiation 
of contraceptive use.45 However, several recent 
studies have addressed strategies for improving 
access to LARC methods. In a cluster-randomized 
trial involving 40 reproductive health clinics across 
the United States, intervention clinics received 
training on contraception counseling and on 
insertion of IUDs and implants, and control 
clinics provided standard care.46 Higher percent-
ages of women at the intervention clinics than at 
the control clinics chose LARC methods (28% vs. 
17%; odds ratio, 2.2; 95% confidence interval, 
1.6 to 3.1).46 The Colorado Family Planning Ini-
tiative used private funding to procure LARC 
methods, to train providers and staff on provision 
of LARC methods, and to provide technical as-
sistance with billing and management issues.47 
LARC use among 15-to-24-year-old persons in 
Colorado increased from 5% to 19% over the 
course of 2 years.47 Progress has been made in 
several U.S. states in resolving inadequate reim-
bursement and other logistic and administrative 
barriers to LARC access, and activities such as 
the LARC Learning Community are addressing 
these issues at the national and state levels.48
More research is needed to determine the 
most appropriate timing of IUD placement after 
a pelvic infection. Evidence is lacking to guide 
health care providers in determining when an 
infection has resolved sufficiently for IUD place-
ment.49 In women who test positive for gonococ-
cal infection or chlamydial infection at the time 
of IUD placement, the device should be left in 
place and treatment should be initiated.17
For women who have human immunodefi-
ciency virus (HIV) infection, limited evidence is 
available with respect to potential interactions 
between the use of hormonal implants and anti-
retroviral medications. A theoretical concern is 
that certain ritonavir-boosted protease inhibitors 
may reduce serum progestin levels, and evidence 
from one retrospective trial suggested increased 
pregnancy rates among women who used both 
etonogestrel implants and efavirenz; however, 
confidence intervals were wide and pregnancy 
rates were still lower than those seen with other 
hormonal methods.17 For women who use certain 
antiretroviral medications that have the poten-
tial for interactions with hormonal implants, 
clinicians should counsel that an increased risk 
of contraceptive failure is possible, as compared 
with hormonal implant users who are not using 
those antiretroviral medications.
The duration of effectiveness of LARC meth-
ods may extend past the currently approved time 
periods.50,51 A recent multicountry study showed 
a 7-year cumulative pregnancy rate of less than 
1 pregnancy per 100 woman-years among women 
who used a 52-mg LNG-IUD.12 In a U.S. study, 
1 pregnancy was reported among 263 women 
who used a 52-mg LNG-IUD during the sixth 
year of use (pregnancy rate, 0.51 per 100 woman-
years), and no pregnancies were reported among 
123 implant users during the fourth year of use 
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or among 34 implant users during the fifth year 
of use.50 A multicountry study showed no preg-
nancies among 204 implant users during the 
fourth and fifth years of use.52 The serum etono-
gestrel levels remained within the thresholds of 
contraceptive effectiveness for the implant through 
4 years of follow-up and did not vary signifi-
cantly according to body-mass index.50 A longer 
period of effectiveness would decrease the need 
for removal and reinsertion procedures. Women 
should also understand that the IUD or implant 
can be removed at any time and that these meth-
ods are appropriate choices for women who plan 
to use them for a shorter time than the approved 
life of the device.
Guidelines
The American College of Obstetricians and Gyne-
cologists and the American Academy of Pediatrics 
recommend that IUDs and the contraceptive im-
plant be offered as first-line methods of contra-
ception to all women, including adolescents.26,53,54 
The CDC publishes recommendations for the 
safe use of contraception, including IUDs and 
implants, for women with various conditions or 
characteristics17; guidance regarding the initia-
tion and use of contraception and the manage-
ment of problems such as irregular bleeding that 
may arise with the use of LARC methods is also 
provided.19 Recommendations provided during 
contraceptive counseling encourage a patient-
centered approach for choosing a contraceptive 
method.55 The recommendations in this article 
are consistent with these guidelines.
Conclusions a nd 
R ecommendations
Adolescents and women of reproductive age who 
wish to prevent pregnancy, such as the 17-year-
old described in the vignette, should be coun-
seled about contraception and should have ac-
cess to the full range of contraceptive methods.19 
All adolescents and adult women should be in-
formed about the availability of LARC methods, 
given their extremely high effectiveness, safety, 
and high rate of continuation. We would counsel 
the adolescent described in the vignette accord-
ingly and would emphasize the superior effec-
tiveness of LARC methods over other reversible 
contraceptive methods, given that she has re-
quested a highly effective method. If no contra-
indications are present, we would provide the 
method of her choice during her initial visit. She 
should also be counseled to use a barrier method 
for prevention of STDs and HIV infection.18 We 
would advise the adolescent about expected 
changes in bleeding patterns with use of LARC 
methods19 and would suggest that she follow up 
as needed for questions or problems.19
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